Last updated: December 24, 2024
Sponsor: Nanjing Children's Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Birth Defects
Holoprosencephaly
Treatment
Inflow occlusion with perforation of septation and sclerotherapy
Perforation of septation and sclerotherapy
Partial resection and sclerotherapy
Clinical Study ID
NCT06275022
NanjingCH011665
Ages 30-16 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
(1) no previous intervention; (2) cLM diagnosed by pretreatment magnetic resonance imaging (MRI); (3)3 to 6 months post-treatment follow-up; (4) Superfacial cLM
Exclusion
Exclusion Criteria:
(1) history of iodine allergy; (2) syndromic cLM ; (3) severe liver and kidney dysfunction; (4) intralesional hemorrhage; (5) intralesional infection
Study Design
Total Participants: 110
Treatment Group(s): 4
Primary Treatment: Inflow occlusion with perforation of septation and sclerotherapy
Phase:
Study Start date:
January 01, 2023
Estimated Completion Date:
June 30, 2026
Connect with a study center
Children's hospital of Nanjing medical university
Nanjing, Jiangsu 210008
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.